Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;62(5):474-485.
doi: 10.1007/s00108-021-00993-3. Epub 2021 Mar 12.

[Long-term treatment concepts for osteoporosis]

[Article in German]
Barbara Obermayer-Pietsch  1 , Ines Fössl  2 , Hans Peter Dimai  2
Affiliations
Review

[Long-term treatment concepts for osteoporosis]

[Article in German]
Barbara Obermayer-Pietsch et al. Internist (Berl). 2021 May.

Abstract
in English, German

The need for a long-term pharmacological treatment of osteoporosis, the problem of potential compliance issues and also potentially severe side effects during the treatment are of central interest not only for patients but also for medical guidelines and prescribers. This review summarizes the current knowledge about the pharmacological substances used and the current scientifically based guidelines and approaches for the long-term use as well as the monitoring and potential treatment changes with a special focus on future developments.

Die Notwendigkeit einer Langzeittherapie bei Osteoporose, eine teils eingeschränkte Compliance, aber auch die Möglichkeit von erheblichen Nebenwirkungen bei einer pharmakologischen Osteoporosetherapie beschäftigen sowohl die medizinischen Richtlinien als auch die Betroffenen in vielfacher Weise. In dieser Übersicht wird auf den Stand der zur Verfügung stehenden Osteoporosepharmazeutika und die aktuellen wissenschaftlich fundierten Grundlagen einer langjährigen Anwendung, das potenzielle Monitoring und mögliche Therapieänderungen mit dem spezifischen Augenmerk auf künftige Entwicklungen eingegangen.

Keywords: Compliance; Drug-related side effects and adverse reactions; Patient monitoring; Pharmaceuticals; Research and development.

PubMed Disclaimer

References

    1. Langdahl B. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone. 2020;139:115516. doi: 10.1016/j.bone.2020.115516. - DOI - PubMed
    1. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–262. doi: 10.1056/NEJMcp1513724. - DOI - PubMed
    1. Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, Brandi ML, Cano A, Collins P, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int. 2020;31(12):2271–2286. doi: 10.1007/s00198-020-05497-8. - DOI - PMC - PubMed
    1. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622. doi: 10.1210/jc.2019-00221. - DOI - PubMed
    1. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809. doi: 10.1056/NEJMoa074941. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources